May 5, 2021 -- Athenex plans to acquire Kurr Therapeutics, including its allogeneic chimeric antigen receptor-natural killer T (CAR-NKT) cell platform, to expand its cell therapy development.
Kurr's platform aids in the development immunotherapies for the treatment of solid and hematological malignancies.
Athenex will pay $70 million upfront to Kurr shareholders, as well as some employees and directors. Additionally, they are eligible to receive up to $115 million in milestone payments. Milestone payments of cash, common stock, or combination would be made at Athenex's sole discretion.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
